美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Xtrackers Nifty 500 India ETF

24.20

+0.05000.21%

成交量：1,944.00

成交額：4.76萬

市值：484.00萬

市盈率：- -

高：24.64

開：24.30

低：24.20

收：24.15

52周最高：27.40

52周最低：23.33

股本：20.00萬

流通股本：20.00萬

量比：1.09

換手率：0.97%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

一份報告砸崩印度IT！AI衝擊擔憂發酵，印度軟件股遭遇大規模拋售

中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准

股海導航_2026年2月24日_滬深股市公告與交易提示

長風藥業(02652)：國家藥監局受理ICF004的IND申請

野村：印度央行在2027年前不太可能降息

环球市场播报

《亞股》亞太股市普遍造好日本及印度股市上揚礦業股力拓跌逾4%

印度央行收緊證券經紀商貸款規則加碼遏制市場投機

环球市场播报

基石藥業：CS2009II期臨床試驗申請獲美國FDA批准

人民幣兑印度盧比漲瘋了，這一波升勢還有上行空間嗎？

九源基因(02566)：JY54注射液IND申請獲CDE正式受理

亞盛醫藥BTK降解劑APG-3288新藥臨床申請（IND）獲CDE許可，全球臨床開發再提速

友芝友生物-B(02496)：M 701取得FDA的IND批准

前沿生物：2025年末公司已就FB7013向國家藥監局提交IND申請並獲受理，FB7013正式進入臨床申請審批通道

英硅智能盤中升逾8%破頂 NLRP3抑制劑ISM8969獲FDA臨床試驗批件

這家藥企又一款新藥臨床申請獲FDA許可，國際化發展持續加速

港股異動 | 康寧傑瑞製藥-B(09966)升逾6% 近日SKN033的一項II期臨床試驗IND申請獲受理

亞盛醫藥BTK降解劑APG-3288的新藥臨床申請（IND）獲美國FDA許可

康希諾：2025年公司4款候選產品已獲得批准IND/NDA

港股異動 | 復宏漢霖(02696)現漲近9% 公司旗下三款實體瘤創新藥IND同期獲受理

歌禮制藥-B(01672)宣佈ASC30在糖尿病受試者中的 13周II期研究IND獲美國FDA批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IND/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.2,"timestamp":1771966800000,"preClose":24.15,"halted":0,"volume":1944,"delay":0,"changeRate":0.0020703933747412305,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"盤前交易","change":0.05,"latestTime":"02-25 06:33:54 EST","open":24.3,"high":24.64,"low":24.2,"amount":47562.7331,"amplitude":0.018219,"askPrice":38.47,"askSize":100,"bidPrice":9.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1772029800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":24.2,"sharesOutstanding":200001,"nav":24.231,"aum":4846213.94,"bidAskSpread":0,"volumeRatio":1.0922904385081846},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0922904385081846,"shares":200001,"dividePrice":0,"high":24.64,"amplitude":0.018219,"preClose":24.15,"low":24.2,"week52Low":23.3301,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":24.2,"eps":0,"divideRate":0,"volume":1944,"delay":0,"ttmEps":0,"open":24.3,"prevYearClose":24.78,"prevWeekClose":24.47,"prevMonthClose":23.8555,"prevQuarterClose":24.78,"fiveDayClose":24.51,"twentyDayClose":23.615,"sixtyDayClose":25.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613675997","title":"一份報告砸崩印度IT！AI衝擊擔憂發酵，印度軟件股遭遇大規模拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2613675997","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613675997?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 15:03","pubTimestamp":1771916638,"startTime":"0","endTime":"0","summary":"在近日研究公司Citrini Research发布报告后，市场对人工智能冲击相关企业的担忧进一步放大，印度软件服务类股遭遇深度抛售。据了解，Citrini发表的报告详细分析AI可能为全球经济多个领域带来潜在风险，设想2028年AI引发白领失业、消费萎缩，以及由软件支援的贷款出现违约、经济陷入收缩的情况。投资者担忧，Anthropic等公司推出的AI工具将持续挤压行业利润率。该报告同样冲击美国市场，物流配送、支付及软件类股普遍走低，$IBM$股价遭遇25年来最大单日跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"一份报告砸崩印度IT！AI冲击担忧发酵，印度软件股遭遇大规模抛售","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VGT","INCO","PIN","BK4588","SMIN","INDL","EPI","INDY","INXX","IMVP","MNDmain","NFTY","INDA","IFN","FLIN","SCIN","BK4585","IND","IBN"],"gpt_icon":0},{"id":"2613717630","title":"中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717630?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","BK1574","IBD","03681"],"gpt_icon":0},{"id":"2613975138","title":"股海導航_2026年2月24日_滬深股市公告與交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975138","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613975138?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 08:30","pubTimestamp":1771893000,"startTime":"0","endTime":"0","summary":"经初步测算，预计本次方案将对公司2026年度归母净利润产生一定负面影响，影响金额低于公司2024年度经审计归母净利润的5%，不会对公司整体业务发展产生实质性影响。　　ST京蓝公告，自2026年1月23日至2026年2月13日期间公司股票价格涨幅为86.90%，短期内价格涨幅较大，公司业绩未发生重大变化，但近期公司股票价格严重脱离公司业绩情况，投资者参与交易可能面临较大风险，如未来公司股票价格进一步异常上涨，公司可能申请停牌核查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-02-24/doc-inhnwmhy3272551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK","GSK.UK","BK4007","BK4588","BK4585","GSKH","LU1829250122.USD","BK4532","IND"],"gpt_icon":0},{"id":"2613753336","title":"長風藥業(02652)：國家藥監局受理ICF004的IND申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753336?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:12","pubTimestamp":1771884770,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，本公司自主研发的吸入粉雾剂候选药物ICF004(产品)的新药临床试验申请(该申请)已获中国国家药品监督管理局受理。ICF004拟用于治疗进行性纤维化间质性肺病，该疾病领域包括特发性肺纤维化及进行性肺纤维化等危及生命的适应症。在已完成的临床前研究中，ICF004经吸入给药后呈现差异化的分布特征，表现为肺组织高暴露量及低全身暴露量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652","IND"],"gpt_icon":0},{"id":"2611102569","title":"野村：印度央行在2027年前不太可能降息","url":"https://stock-news.laohu8.com/highlight/detail?id=2611102569","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611102569?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 17:18","pubTimestamp":1771233480,"startTime":"0","endTime":"0","summary":"野村（Nomura）研究分析师称，印度央行预计将维持利率不变，至少到2027年底。这些分析师在一份报告中写道，新CPI系列下的通胀走强以及更积极的增长前景意味着印度央行不太可能很快降息。\n　　这些分析师补充说，通胀轨迹基本未变，新的CPI系列预计不会改变印度央行的看法，即基本通胀依然温和，且牢牢锚定在其4%的中期目标。这些分析师称，与美国和欧盟的贸易协议、印度的“扩张性“预算以及以往降息的滞后效应，也都为2027财年更强劲的GDP增长奠定了基础。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘明亮","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2026-02-16/doc-inhmzfsf9971334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["INDY","FLIN","BK4585","SMIN","BK4588","EPI","IND","NFTY","BK4523","HK0000934320.USD","INDL","IMVP","SCIN","PIN","INDA"],"gpt_icon":0},{"id":"2611204103","title":"《亞股》亞太股市普遍造好 日本及印度股市上揚 礦業股力拓跌逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611204103","media":"AASTOCKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611204103?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 13:00","pubTimestamp":1771218000,"startTime":"0","endTime":"0","summary":"美国上月通胀低于预期，核心通胀符预期，美股道指上周五(13日)升0.1%。亚太股市今早(16日)普遍造好，多个市场假期休市。沪深股市及台股休市，港股恒指半日市升138点或0.5%，收26,705点，成交850亿元。日股反复造好，日经平均指数升109点或0.2%，报57,051点。软银升6.5%，Sanrio升6%，索尼...","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250827160502599_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250827160502599_s.jpg"],"rights":{"source":"aastocks_forex","url":"https://www.aastocks.com/sc/forex/news/comment.aspx?source=AAFN&id=NOW.1503594&catg=1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.aastocks.com/sc/forex/news/comment.aspx?source=AAFN&id=NOW.1503594&catg=1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_forex","symbols":["BK4585","INDA","SMIN","BK4588","INDL","IND","SCIN","INDY","EPI","BK4168","NFTY","PIN","RIO","FLIN","BK4523"],"gpt_icon":0},{"id":"2611310850","title":"印度央行收緊證券經紀商貸款規則 加碼遏制市場投機","url":"https://stock-news.laohu8.com/highlight/detail?id=2611310850","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611310850?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 11:58","pubTimestamp":1771214280,"startTime":"0","endTime":"0","summary":"印度央行收紧对从事股票和大宗商品自营交易、并向客户提供杠杆的机构的贷款规则，这是印度监管部门为抑制投机性市场活动推出的最新举措。　　根据印度央行周五晚些时候发布在网站上的一项公告，所有向证券经纪商提供的信贷都必须有抵押物作担保，而向经纪商提供用于自营交易或投资的贷款则被禁止。央行表示，针对股票和商品经纪商等资本市场中介机构的这项审慎监管规则将于4月1日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-16/doc-inhmyquk6275401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EPI","BK4523","INDA","SCIN","INDL","PIN","SMIN","161027","NFTY","BK4588","FLIN","IND","BK4585","INDY"],"gpt_icon":0},{"id":"2611017176","title":"基石藥業：CS2009II期臨床試驗申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611017176","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611017176?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 08:17","pubTimestamp":1771201057,"startTime":"0","endTime":"0","summary":"【基石药业：CS2009II期临床试验申请获美国FDA批准】2月16日，基石药业在港交所公告，公司核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）用于晚期实体瘤的II期新药临床试验（IND）申请已经获得美国食品药品监督管理局（FDA）批准。CS2009用于晚期实体瘤的II期IND申请获FDA批准，标志着这一创新免疫疗法的全球开发取得重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202602163651161217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IND"],"gpt_icon":0},{"id":"2611205185","title":"人民幣兑印度盧比漲瘋了，這一波升勢還有上行空間嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2611205185","media":"FX168","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611205185?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 11:31","pubTimestamp":1770953489,"startTime":"0","endTime":"0","summary":"FX168财经报社 讯 分析师表示，由于印度与中国在货币管理方式上正出现分化，人民币兑印度卢比的这轮上涨可能仍有进一步空间。澳新银行预计，到年底卢比兑人民币将走弱至13.58。马来亚银行预计该汇率到12月将向13.30靠拢；印度Emkay Global Financial Services则认为，人民币兑卢比可能在未来3到6个月触及13.30。人民币的走势对印度很重要，因为中国是印度最大的进口来源国，两国双边贸易仍在扩大。去年人民币兑卢比大涨近10%，为12年来最大涨幅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fx168news.com/article/人民币-995645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLIN","INDY","EPI","SMIN","INDA","IND","BK4588","UCmain","INDL","CYB","PIN","NFTY","BK4585","SCIN","MUCmain","BK4523","CNHmain","MCNHmain"],"gpt_icon":0},{"id":"2610600638","title":"九源基因(02566)：JY54注射液IND申請獲CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610600638?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司自主开发的化学1类创新药JY54 注射液新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外，在与已上市肥胖治疗药物的联合应用研究中，JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析，JY54注射液有望支持长效给药方案，并在体重管理领域展现差异化的临床应用潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1223083913.SGD","CDE","02566","IND","LU1223082519.USD","LU1223082196.USD","BK4017"],"gpt_icon":0},{"id":"2609095558","title":"亞盛醫藥BTK降解劑APG-3288新藥臨床申請（IND）獲CDE許可，全球臨床開發再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK4144","LU2125909916.SGD","CDE","IND","LU1223082519.USD","APG","LU1223083913.SGD","LU1923622291.USD","LU2125909759.SGD","TK","BK1574","BK4139","LU1223082196.USD","BK4017","AAPG","BK1161","BK4129"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496)：M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608824493?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，于2026年1月31日，注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准，标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段，为全球患者带来新希望。M 701精准靶向Ep CAM和CD3，其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达，是关键治疗靶点;CD3可激活机体抗肿瘤免疫，二者协同实现精准治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02496"],"gpt_icon":0},{"id":"2606243834","title":"前沿生物：2025年末公司已就FB7013向國家藥監局提交IND申請並獲受理，FB7013正式進入臨床申請審批通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2606243834","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606243834?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 20:05","pubTimestamp":1769429100,"startTime":"0","endTime":"0","summary":"关于BD合作事宜，公司始终秉持开放的态度，积极探索符合产品发展战略的合作机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688221","IND"],"gpt_icon":0},{"id":"2605428112","title":"英硅智能盤中升逾8%破頂 NLRP3抑制劑ISM8969獲FDA臨床試驗批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2605428112","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605428112?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 11:29","pubTimestamp":1769138966,"startTime":"0","endTime":"0","summary":"英硅智能盘中涨超8%，高见64.40港元，创上市新高。英硅智能今日宣布，其用于炎症及神经退行性疾病治疗的口服NLRP3抑制剂ISM8969临床试验新药申请获得美国食品药品监督管理局批准，用于帕金森病治疗。值得一提的是，为加速ISM8969的全球开发，英硅智能已与衡泰生物达成共同开发合作协议。双方各持有该项目50%的全球权益，同时英硅智能有权获得最高逾5亿港币的预付款和里程碑付款。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/01/23112955220421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IND","PSI"],"gpt_icon":0},{"id":"2602347075","title":"這家藥企又一款新藥臨床申請獲FDA許可，國際化發展持續加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2602347075","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602347075?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 15:42","pubTimestamp":1767858161,"startTime":"0","endTime":"0","summary":"近日，亚盛医药宣布BTK降解剂APG-3288的新药临床申请获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。截至目前，公司已共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定，2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。业内预计，随着亚盛医药重磅品种临床的持续推进，以及与跨国药企及顶尖学术机构的深度合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ASPHF","IND"],"gpt_icon":0},{"id":"2601336363","title":"港股異動 | 康寧傑瑞製藥-B(09966)升逾6% 近日SKN033的一項II期臨床試驗IND申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336363?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 10:10","pubTimestamp":1767838222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","IND","09966"],"gpt_icon":0},{"id":"2601824845","title":"亞盛醫藥BTK降解劑APG-3288的新藥臨床申請（IND）獲美國FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824845","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824845?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 09:30","pubTimestamp":1767749400,"startTime":"0","endTime":"0","summary":"临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力5。此次APG-3288的IND获美国FDA许可，是我们在这一领域的重大里程碑。我们将快速推进APG-3288的全球临床开发，积极探索蛋白降解剂这一新分子实体在血液肿瘤及其他BTK相关疾病中的治疗潜力，早日惠及更多患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4858031_ZH58031_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","IND","LU2125909916.SGD","AAPG","06855","LU1923622291.USD","BK4129","TK","BK4139","BK4144","LU2125909759.SGD","BK1161","APG"],"gpt_icon":0},{"id":"2601890033","title":"康希諾：2025年公司4款候選產品已獲得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890033?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端，2025年公司4款候选产品已获得批准IND/NDA，以及启动2个新的临床试验，以2026年设置的业绩考核目标A档来看，2026年至少包括5款候选产品获得批准IND、获得批准NDA，以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进，公司也会和药监、中检院及临床试验合作方等积极沟通，以期顺利推进相应候选产品的研发里程碑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688185","IND","BK0239"],"gpt_icon":0},{"id":"2601071879","title":"港股異動 | 復宏漢霖(02696)現漲近9% 公司旗下三款實體瘤創新藥IND同期獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601071879","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601071879?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 11:02","pubTimestamp":1767582152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖(02696)现涨近9%，截至发稿，涨8.62%，报63.65港元，成交额2904.28万港元。消息面上，12月30日，复宏汉霖宣布，公司三款潜力创新分子——基于自研T细胞衔接器（TCE）平台开发的DLL3xDLL3xCD3xCD28四特异性TCE HLX3901、潜在同类最优（BIC）的新型KAT6A/B口服小分子抑制剂HLX97、以及潜在同类首创（FIC）的B7H3-唾液酸酶融合蛋白HLX316的新药临床试验申请均已获得国家药品监督管理局受理。以上三款产品皆拟用于实体肿瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","02696","BK1574","HK0000165453.HKD","BK1161","159992","IND"],"gpt_icon":0},{"id":"2601785620","title":"歌禮制藥-B(01672)宣佈ASC30在糖尿病受試者中的 13周II期研究IND獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601785620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601785620?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 08:13","pubTimestamp":1767572009,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，近期已获得美国食品药品监督管理局 对其口服小分子GLP-1，ASC30，在糖尿病受试者中的II期研究的新药临床试验的批准。该II期研究是一项为期13周、随机、双盲、安慰剂对照及多中心的研究，旨在评估ASC30在2型糖尿病受试者中的疗效、安全性和耐受性。歌礼已于近期完成其评估口服小分子GLP-1受体激动剂ASC30治疗肥胖症的13周II期研究。在ASC30用于治疗肥胖或超重的II期研究中，因不良事件导致的总体停药率为4.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f1a65319f224684be7c4d1ad3324a2f2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1574","IND","BK1191","BK1161","01477"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}